Table 4.
Prospective studies investigating post-transplant pharmacologic interventions to prevent hematologic relapse of acute myelogenous leukemia in adults
WT-1 indicates Wilms tumor-1; AML, acute myelogenous leukemia; MDS, myelodysplastic syndrome; HSCT, hematopoietic stem cell transplant; NK, natural killer; IL-2, interleukin-2; TBI, total body irradiation; CR, complete remission; SQ, subcutaneously; GVHD, graft-versus-host disease; FLT3-ITD, FLT3-Internal tandem duplication; and MRD, minimal residual disease.
